Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
TGTX 
TG Therapeutics Inc (TGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: TGTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $40.5
1 Year Target Price $40.5
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 35.53% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.65B USD | Price to earnings Ratio 77.18 | 1Y Target Price 40.5 |
Price to earnings Ratio 77.18 | 1Y Target Price 40.5 | ||
Volume (30-day avg) 7 | Beta 1.95 | 52 Weeks Range 21.11 - 46.48 | Updated Date 08/30/2025 |
52 Weeks Range 21.11 - 46.48 | Updated Date 08/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.38 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-04 | When - | Estimate 0.19 | Actual 0.17 |
Profitability
Profit Margin 13.32% | Operating Margin (TTM) 24.69% |
Management Effectiveness
Return on Assets (TTM) 9.72% | Return on Equity (TTM) 26.63% |
Valuation
Trailing PE 77.18 | Forward PE 42.92 | Enterprise Value 4596802152 | Price to Sales(TTM) 10.25 |
Enterprise Value 4596802152 | Price to Sales(TTM) 10.25 | ||
Enterprise Value to Revenue 10.12 | Enterprise Value to EBITDA 47.11 | Shares Outstanding 158666000 | Shares Floating 135140097 |
Shares Outstanding 158666000 | Shares Floating 135140097 | ||
Percent Insiders 9.74 | Percent Institutions 64.61 |
Upturn AI SWOT
TG Therapeutics Inc
Company Overview
History and Background
TG Therapeutics, Inc. was founded in 1997. It is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell malignancies and autoimmune diseases. It has evolved from early research to commercializing its first product, Briumvi.
Core Business Areas
- Hematologic Oncology: Focuses on the development and commercialization of therapies for B-cell malignancies like multiple sclerosis.
Leadership and Structure
Michael S. Weiss is the Chairman and Chief Executive Officer. The company has a board of directors and operates with a functional organizational structure, focused on research, development, and commercialization.
Top Products and Market Share
Key Offerings
- Briumvi (Ublituximab-xiiy): Briumvi is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (RMS). Its competitors include Ocrevus (Roche), Kesimpta (Novartis), Tysabri (Biogen), Gilenya (Novartis), Mayzent (Novartis).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive. The market for multiple sclerosis therapies is large and growing, with increasing demand for effective treatments.
Positioning
TG Therapeutics is positioned as a company developing and commercializing novel therapies for autoimmune diseases and B-cell malignancies with an aim to address unmet medical needs. They are trying to secure their spot in the multiple sclerosis market.
Total Addressable Market (TAM)
The global multiple sclerosis market is estimated to reach over $30 billion. TG Therapeutics is positioned to capture a share of this market with Briumvi, especially if they demonstrate superior efficacy or cost-effectiveness.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (Briumvi)
- Experienced management team
- Focus on specific disease areas
- FDA Approved drug Briumvi
Weaknesses
- Reliance on single product for revenue
- Limited commercial infrastructure compared to larger competitors
- Historical operating losses
- Relatively small Market Capitalization
Opportunities
- Expansion into new indications
- Partnerships with larger pharmaceutical companies
- Further clinical development of pipeline assets
- Increase Market share of Briumvi
Threats
- Competition from established players
- Regulatory hurdles
- Patent expirations
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- RHHBY
- NVS
- BIIB
Competitive Landscape
TG Therapeutics faces strong competition from established pharmaceutical companies. Their competitive advantage lies in their novel therapeutic approach and focus on specific patient populations. Success will depend on demonstrating superior efficacy and cost-effectiveness.
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by clinical development and regulatory milestones. The launch of Briumvi marks a significant turning point.
Future Projections: Future growth depends on the successful commercialization of Briumvi and expansion into new indications. Analyst estimates vary but generally project revenue growth.
Recent Initiatives: Commercial launch of Briumvi, ongoing clinical trials, and potential partnerships.
Summary
TG Therapeutics is a biopharmaceutical company that is now in the commercialization phase with Briumvi, which targets a growing market for MS treatments. While Briumvi is promising, the company faces risks associated with their size, heavy competition, and dependence on one product. Investors should watch for Briumvi sales growth and R&D expenses. Future success lies in growing revenue from Briumvi, maintaining financial discipline, and continuing pipeline development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About TG Therapeutics Inc
Exchange NASDAQ | Headquaters Morrisville, NC, United States | ||
IPO Launch date 1995-12-14 | Chairman, CEO & President Mr. Michael S. Weiss Esq., J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 370 | Website https://www.tgtherapeutics.com |
Full time employees 370 | Website https://www.tgtherapeutics.com | ||
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.